K A Schoedel

Summary

Affiliation: Utrecht Institute for Pharmaceutical Sciences (UIPS

Publications

  1. ncbi A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use
    Kerri Alexandra Schoedel
    Kendle Early Stage Toronto, Toronto, Ontario, Canada
    Hum Psychopharmacol 26:224-36. 2011
  2. ncbi Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users
    K A Schoedel
    Kendle Early Stage Toronto, Ontario, Canada
    Clin Pharmacol Ther 88:69-78. 2010
  3. ncbi Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone
    Kerri A Schoedel
    Kendle Early Stage, Toronto, ON, Canada
    Pain Physician 13:561-73. 2010
  4. doi Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users
    M J Shram
    Kendle Early Stage, Toronto, Ontario, Canada
    Clin Pharmacol Ther 89:683-92. 2011
  5. ncbi Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain
    K A Schoedel
    Department of Pharmacology, University of Toronto, 1 King's College Circle, M5S 1A8, Toronto, Ontario, Canada
    Biochem Pharmacol 62:1025-36. 2001
  6. doi Assessing abuse liability during drug development: changing standards and expectations
    K A Schoedel
    Clinical Pharmacology Group, DecisionLine Clinical Research Corporation, Toronto, Ontario, Canada
    Clin Pharmacol Ther 83:622-6. 2008
  7. doi Update on tamper-resistant drug formulations
    M K Romach
    DL Global Partners Inc, Toronto, ON, Canada
    Drug Alcohol Depend 130:13-23. 2013

Detail Information

Publications7

  1. ncbi A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use
    Kerri Alexandra Schoedel
    Kendle Early Stage Toronto, Toronto, Ontario, Canada
    Hum Psychopharmacol 26:224-36. 2011
    ..This study aimed to evaluate the abuse potential and cognitive effects of nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD)...
  2. ncbi Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users
    K A Schoedel
    Kendle Early Stage Toronto, Ontario, Canada
    Clin Pharmacol Ther 88:69-78. 2010
    ..These results demonstrate that the abuse potential for tesofensine is no greater than that of bupropion or atomoxetine, and tesofensine is therefore unlikely to be recreationally abused...
  3. ncbi Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone
    Kerri A Schoedel
    Kendle Early Stage, Toronto, ON, Canada
    Pain Physician 13:561-73. 2010
    ..Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects...
  4. doi Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users
    M J Shram
    Kendle Early Stage, Toronto, Ontario, Canada
    Clin Pharmacol Ther 89:683-92. 2011
    ..The findings suggest that, at supratherapeutic doses, lorcaserin is associated with distinct, primarily negative, subjective effects and has low abuse potential...
  5. ncbi Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain
    K A Schoedel
    Department of Pharmacology, University of Toronto, 1 King's College Circle, M5S 1A8, Toronto, Ontario, Canada
    Biochem Pharmacol 62:1025-36. 2001
    ....
  6. doi Assessing abuse liability during drug development: changing standards and expectations
    K A Schoedel
    Clinical Pharmacology Group, DecisionLine Clinical Research Corporation, Toronto, Ontario, Canada
    Clin Pharmacol Ther 83:622-6. 2008
    ....
  7. doi Update on tamper-resistant drug formulations
    M K Romach
    DL Global Partners Inc, Toronto, ON, Canada
    Drug Alcohol Depend 130:13-23. 2013
    ....